Ozempic could help patients with advanced Alzheimer’s disease, scientists believe. Trials are underway examining the impact ...

Two clinical trials investigating semaglutide (Ozempic, Wegovy) as an early Alzheimer's treatment are expected to wrap up in ...

Alzheimer's, addiction, cardiovascular diseases, kidney disorders, sleep apnoea, diabetes, obesity, and overweight.

“Among adults, 5.4% of all prescriptions in September 2024 were for GLP-1s,” Rodriguez says. That is up from 3.5% a year ...

Taxi and ambulance drivers have jobs that "demand real-time spatial and navigational processing," said the lead researcher, ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Opens in a new tab or window Two clinical trials investigating semaglutide (Ozempic, Wegovy) as an early Alzheimer's treatment are expected to wrap up in 2025. (New Scientist) Researchers say stem ...

Ozempic could help patients with advanced Alzheimer’s disease, scientists believe. Trials are underway examining the impact of semaglutide – marketed as Ozempic for the treatment of diabetes ...

In 1987, fewer than one in five American adults were obese, and by 1999, obesity was responsible for more than 300,000 excess ...

Ozempic could be given to help patients with advanced Alzheimer’s disease, it was claimed last night. Scientists believe the weight-loss jab’s role in reducing inflammation in the body is key ...

Taxi and ambulance drivers are at a lower risk of an Alzheimer's disease-related death, a new study finds. Related: Ozempic May Be Linked to Lower Risk of Alzheimer’s in People with Type 2 ...